Podium to Practice: ASH® 2025 – MULTIPLE MYELOMA: Daratumumab vs Observation in High-Risk SMM: AQUILA Outcomes by Risk and Age

Podium to Practice: ASH® 2025 – MULTIPLE MYELOMA: Daratumumab vs Observation in High-Risk SMM: AQUILA Outcomes by Risk and Age

Podium to Practice: ASH® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Donna Reece

Icon Chair Speaker

Speakers

Dr. Darrell White

Dr. Maria Victoria Mateos Manteca

Studies / Trials Discussed

ID 372 – Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Studies/trials discussed:

ID 372 – Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age
Tagged